Table 1 Clinical and pathological characteristics of patients in the RESPECT and trans-RESPECT cohorts

From: HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy

 

RESPECT

Trans-RESPECT

 

All patients

All patients

H arm

H + CT arm

HER2DX low-risk

HER2DX high-risk

N

266

154

74

80

114

40

Mean age

73.9

73.7

73.6

73.9

73.6

74.3

ER+ disease

47.7%

44.2%

41.9%

46.3%

46.5%

37.5%

pT stage

 pT 1

48.9%

51.3%

52.7%

50.0%

61.4%

22.5%

 pT1b

16.2%

19.0%

15.4%

22.5%

21.4%

0.0%

 pT1c

83.8%

81.0%

84.6%

77.5%

78.6%

100.0%

 pT 2–3

51.1%

48.7%

47.3%

50.0%

38.6%

77.5%

 pT2

94.1%

92.0%

85.7%

97.5%

90.9%

93.5%

 pT3

5.9%

8.0%

14.3%

2.5%

9.1%

6.5%

pN stage

 pN 0

80.5%

83.8%

90.5%

77.5%

96.5%

47.5%

 pN 1–3

17.7%

16.2%

9.5%

22.5%

3.5%

52.5%

 Unknown

1.9%

TILs

 <20%

63.4%

63.0%

63.8%

59.3%

75.0%

 ≥20%

36.6%

37.0%

36.2%

40.7%

25.0%

HER2DX pCR score

 Med/Low

48.7%

44.6%

52.5%

53.5%

55.0%

 High

51.3%

55.4%

47.5%

46.5%

45.0%

HER2DX ERBB2 score

 Low

20.1%

20.3%

20.0%

12.5%

22.8%

 Med

20.8%

23.0%

18.8%

15.0%

22.8%

 High

59.1%

56.7%

61.2%

72.5%

54.4%

  1. Baseline characteristics are shown for all patients enrolled in the RESPECT trial (n = 266) and for the subset included in the present biomarker analysis (Trans-RESPECT, n = 154), as well as stratified by treatment arm (trastuzumab alone [H] vs trastuzumab plus chemotherapy [H + CT]) and by HER2DX risk score group (low-risk vs high-risk).
  2. ER estrogen receptor, pT pathological tumor size, pN pathological nodal status, TILs tumor-infiltrating lymphocytes, NA not available.